Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz2. fázis

TNF-α Treatment of Blast-Induced Tinnitus

A legfontosabb adatok

Ki végzi
Wayne State University
Hol
Celebration, Coral Gables, Detroit és Farmington Hills (Egyesült Államok)Mind a 4 helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Fázis
2. fázis
Résztvevők
88 fő, tervezett
Kezdés
2022. júl. 1.
Várható befejezés
2027. febr.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Etanercept
  • Saline
A regiszteradat frissítve
2026. október 20.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • Tinnitus of at least a moderate severity as defined by a score of ≥ 25 points or higher on the Tinnitus Functional Index (TFI) questionnaire associated with one or more of the following:; Blast- or noise exposure; Traumatic brain injury (TBI) and/or concussion diagnosed by a health care provider
  • Able to provide written informed consent
  • Age: Minimum 18 years of age at the time of enrollment
  • Other concurrent treatments for tinnitus: A four-week washout from any other tinnitus treatment or management program is required prior to entering this study; Hearing aids are permitted if the participant has been wearing them for at least 4 weeks
  • Hearing function: All degrees of hearing function can be included, recognizing that individuals with profound, bilateral hearing loss will not be able to perform tinnitus evaluations and hearing tests but will be able to rate subjective tinnitus loudness, annoyance and impact on life. This is an important sub-population because of the challenges in treating them with acoustic therapy and the need for a medical intervention
  • Additional tinnitus characteristics:; Tinnitus history: Onset associated with blast and/or noise exposure or associated with diagnosed TBI and/or concussion. Subjects will have blast exposure, noise exposure, traumatic brain injury (TBI), and/or concussion impact, defined as exposure/impact less than or longer than six months at time of enrollment; Participants enrolled with tinnitus associated with TBI and/or concussion must have received a diagnosis of TBI and/or concussion by a health care provider; Stability: Constant (not pulsatile or intermittent). c) Location of tinnitus perception: Unrestricted. Tinnitus may be unilateral, bilateral, or perceived in the head

Ki nem vehet részt

  • History or evidence of any of the following: Significant brain malformation; cerebral vascular events (such as strokes); neurodegenerative disorders affecting the brain, such as Parkinson's disease, ALS, or Huntington's disease; multiple sclerosis, Guillain-Barré syndrome, or any other disease involving demyelination disorder or any finding suggesting a demyelination disease or disorder; prior brain surgery; The following surgical procedures are not exclusionary: Evacuation of subdural hematoma, insertion of intracranial pressure monitor device, craniectomy
  • Scheduled to receive a live vaccine during study participation or received a live vaccine within 2 weeks prior to screening visit/procedures
  • Ongoing treatment with or plans to begin taking any of the following contraindicated medications: Cyclophosphamide or sulfasalazine; abatacept, anakinra, or any other immunomodulatory biologic therapy; sulfonylureas, meglitinides, or insulin
  • Subjects who have participated in a drug clinical trial within the last 30 days before the start of this one
  • Active malignant neoplasm such as lymphoma or solid tumors or history of malignant neoplasm, excluding successfully treated squamous cell carcinoma or basal carcinoma of the skin or cervical cancer
  • Diagnosis of congestive heart failure
  • History of diagnosed seizure disorder or epilepsy
  • Subjects who currently have an active infection, including tuberculosis, HIV, hepatitis B, and/or chicken pox; Patients with latent hepatitis B infection are also excluded from participation
  • Diagnosis of an auto-immune disease that, in the opinion of the investigator, would cause a weakened immune system; Autoimmune thyroid disease is not considered an exclusionary autoimmune disease for participation in this study
  • Diabetes
  • Diagnosis of myelodysplastic syndrome or aplastic anemia, white blood cell count < 4000, or platelet count < 150,000
  • Clinically significant out of range laboratory values for protocol required laboratory tests as assessed by the investigator
  • Women who are lactating or are of child-bearing-age without use of contraception
  • Subjects who cannot communicate reliably with research team members or who are not likely to be able to complete the requirements of the trial per the discretion of the investigator
  • Pregnancy or planned pregnancy during the study
  • MMSE score < 24

Helyszínek itt: Egyesült Államok

  • Advent HealthCelebration, Egyesült Államok
  • University of MiamiCoral Gables, Egyesült Államok
  • Wayne State UniversityDetroit, Egyesült Államok
  • Michigan Ear InstituteFarmington Hills, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this multi-site research study is to determine if Etanercept, compared to a placebo, significantly reduces the severity of tinnitus (ringing in the ears) associated with history of blast and/or noise exposure or associated with Traumatic Brain Injury (TBI) and/or concussion. Individuals who qualify will be randomized into one of two groups: The group receiving the medication Etanercept or the group receiving a saline solution placebo.

A vizsgálat 2 csoportja

  • Etanercept Injection GroupA vizsgált kezelés

    Subjects will receive 2 X 25mg/ 1ml etanercept injection (experimental) weekly for 12 weeks.

    Kezelés: Etanercept

  • Placebo Injection GroupPlacebo, összehasonlításként

    Subjects will receive 2 X 1ml saline injection (placebo) weekly for 12 weeks.

    Kezelés: Saline

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Clinical Trial of Etanercept (TNF-α Blocker) for Treatment of Blast-Induced Tinnitus
A regiszteradat frissítve
2026. október 20.